CONFLICTS OF INTEREST
The authors declare no conflicts of interest.
1 Hunger, S. P. & Mullighan, C. G. Acute Lymphoblastic Leukemia in Children. N Engl J Med 373 , 1541-1552, doi:10.1056/NEJMra1400972 (2015).
2 Cooper, S. L. & Brown, P. A. Treatment of pediatric acute lymphoblastic leukemia. Pediatr Clin North Am 62 , 61-73, doi:10.1016/j.pcl.2014.09.006 (2015).
3 Parker, C. et al. Effect of mitoxantrone on outcome of children with first relapse of acute lymphoblastic leukaemia (ALL R3): an open-label randomised trial. Lancet 376 , 2009-2017, doi:10.1016/S0140-6736(10)62002-8 (2010).
4 Meyr, F. et al. Outcomes of treatment for relapsed acute lymphoblastic leukaemia in children with Down syndrome. Br J Haematol 162 , 98-106, doi:10.1111/bjh.12348 (2013).
5 Iqbal, A., Weinstein, J., Angelova, V., Dighe, D. & Giordano, L. A Rare Case of Spontaneous Remission of Terminal Deoxynucleotidyl Transferase Negative B-acute Lymphoblastic Leukemia. J Pediatr Hematol Oncol 40 , e176-e178, doi:10.1097/MPH.0000000000000906 (2018).
6 Yoruk, A. et al. Spontaneous remission of acute lymphoblastic leukemia with mediastinal mass. Pediatr Hematol Oncol25 , 181-186, doi:10.1080/08880010801938132 (2008).
7 Hores, T., Wendelin, K. & Schaefer-Eckart, K. Spontaneous remission of acute lymphoblastic leukemia: A case report. Oncol Lett15 , 115-120, doi:10.3892/ol.2017.7288 (2018).
8 Vachhani, P. et al. Spontaneous Remission in an Older Patient with Relapsed FLT3 ITD Mutant AML. Case Rep Hematol2016 , 1259759, doi:10.1155/2016/1259759 (2016).
9 Pal, S. K. et al. Clinical Cancer Advances 2019: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology. J Clin Oncol 37 , 834-849, doi:10.1200/JCO.18.02037 (2019).
10 Teachey, D. T. & Hunger, S. P. Predicting relapse risk in childhood acute lymphoblastic leukaemia. Br J Haematol 162 , 606-620, doi:10.1111/bjh.12442 (2013).
11 Bhojwani, D. & Pui, C. H. Relapsed childhood acute lymphoblastic leukaemia. Lancet Oncol 14 , e205-217, doi:10.1016/S1470-2045(12)70580-6 (2013).
12 Jabbour, E., Pui, C. H. & Kantarjian, H. Progress and Innovations in the Management of Adult Acute Lymphoblastic Leukemia. JAMA Oncol4 , 1413-1420, doi:10.1001/jamaoncol.2018.1915 (2018).
13 Raanani, P. et al. Salvage therapy of refractory and relapsed acute leukemia with high dose mitoxantrone and high dose cytarabine.Leuk Res 23 , 695-700, doi:10.1016/s0145-2126(99)00078-8 (1999).
14 Fuster, J. Current approach to relapsed acute lymphoblastic leukemia in children. World J Hematol 3 , 49-70, doi:10.5315/wjh.v3.i3.49 (2014).
15 Parker, C. et al. Outcomes of patients with childhood B-cell precursor acute lymphoblastic leukaemia with late bone marrow relapses: long-term follow-up of the ALLR3 open-label randomised trial.Lancet Haematol 6 , e204-e216, doi:10.1016/S2352-3026(19)30003-1 (2019).
16 Buitenkamp, T. D. et al. Acute lymphoblastic leukemia in children with Down syndrome: a retrospective analysis from the Ponte di Legno study group. Blood 123 , 70-77, doi:10.1182/blood-2013-06-509463 (2014).
17 Maloney, K. W. et al. Down syndrome childhood acute lymphoblastic leukemia has a unique spectrum of sentinel cytogenetic lesions that influences treatment outcome: a report from the Children’s Oncology Group. Blood 116 , 1045-1050, doi:10.1182/blood-2009-07-235291 (2010).
18 Whitlock, J. A. Down syndrome and acute lymphoblastic leukaemia.Br J Haematol 135 , 595-602, doi:10.1111/j.1365-2141.2006.06337.x (2006).
19 Paul, S., Rausch, C. R., Nasnas, P. E., Kantarjian, H. & Jabbour, E. J. Treatment of relapsed/refractory acute lymphoblastic leukemia.Clin Adv Hematol Oncol 17 , 166-175 (2019).
20 Bierman, H. R. et al. Remissions in leukemia of childhood following acute infectious disease: staphylococcus and streptococcus, varicella, and feline panleukopenia. Cancer 6 , 591-605, doi:10.1002/1097-0142(195305)6:3<591::aid-cncr2820060317>3.0.co;2-m (1953).
21 Lynggaard, L. S., Marquart, H. V., Kjeldsen, E., Madsen, H. O. & Hasle, H. Acute Lymphoblastic Leukemia Presenting With Pancytopenia Followed by a 14-Month-Long Period of Transient Remission Possibly Supporting the Adrenal Hypothesis of Leukemogenesis. J Pediatr Hematol Oncol 38 , e271-e273, doi:10.1097/MPH.0000000000000648 (2016).
22 Jimemez, C. et al. Increased serum tumour necrosis factor during transient remission in acute leukaemia. Lancet341 , 1600, doi:10.1016/0140-6736(93)90739-4 (1993).
23 Musto, P. et al. Spontaneous remission in acute myeloid leukaemia: a role for endogenous production of tumour necrosis factor and interleukin-2? Br J Haematol 87 , 879-880, doi:10.1111/j.1365-2141.1994.tb06761.x (1994).
24 Helbig, D. et al. Spontaneous Remission in a Patient With Acute Myeloid Leukemia Leading to Undetectable Minimal Residual Disease.J Hematol 9 , 18-22, doi:10.14740/jh606 (2020).
25 Rashidi, A. & Fisher, S. I. Spontaneous remission of acute myeloid leukemia. Leuk Lymphoma 56 , 1727-1734, doi:10.3109/10428194.2014.970545 (2015).